Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells.

Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells.
复制标题

DOI:
10.18632/oncotarget.2017
复制
发表时间:
2014-07-15
期刊:
影响因子:
--
通讯作者:
Ryan AJ
Ryan AJ
中科院分区:
其他
文献类型:
--
作者:
Bokobza SM;Jiang Y;Weber AM;Devery AM;Ryan AJ

文献摘要

参考文献

被引文献

相似文献

尽管EGFR突变阳性(EGFR M+)肿瘤的非小细胞肺癌(NSCLC)患者最初对EGFR酪氨酸激酶抑制剂(TKI)单药治疗反应良好,但反应通常不完全。在这项研究中,我们表明AKT抑制,最重要的是AKT 2抑制,与EGFR TKI抑制协同作用,增加了EGFR M+ NSCLC细胞的细胞杀伤。然而,我们的数据还表明,协同促凋亡作用可能是由于AKT抑制诱导的促生存自噬反应而受到阻碍。因此,用氯喹抑制自噬显著增强了体外EGFR M+细胞中由吉非替尼和AKT抑制剂诱导的肿瘤细胞死亡,并在体内EGFR M+异种移植物中产生更大的肿瘤收缩。总之,我们的研究结果表明,在EGFR和AKT抑制中加入氯喹有可能改善EGFR M+ NSCLC的肿瘤缓解,并且选择性靶向AKT 2可能为NSCLC提供新的治疗选择。
Although non-small cell lung cancer (NSCLC) patients with EGFR mutation positive (EGFR M+) tumors initially respond well to EGFR tyrosine kinase inhibitor (TKI) monotherapy, the responses are usually incomplete. In this study we show that AKT inhibition, most importantly AKT2 inhibition, synergises with EGFR TKI inhibition to increase cell killing in EGFR M+ NSCLC cells. However, our data also suggest that the synergistic pro-apoptotic effects may be stunted due to a prosurvival autophagy response induced by AKT inhibition. Consequently, inhibiting autophagy with chloroquine significantly enhanced tumor cell death induced by gefitinib and AKT inhibitors in EGFR M+ cells in vitro, and produced greater tumor shrinkage in EGFR M+ xenografts in vivo. Together, our findings suggest that adding chloroquine to EGFR and AKT inhibition has the potential to improve tumor responses in EGFR M+ NSCLC, and that selective targeting of AKT2 may provide a new treatment option in NSCLC.
DOI: 10.1111/j.1349-7006.2011.02025.x
发表时间: 2011-10-01
期刊: CANCER SCIENCE
影响因子: 5.7
作者:
Lee, Myoung W.;Kim, Dae S.;Koo, Hong H.
通讯作者: Koo, Hong H.
DOI: 10.1056/nejmoa044238
发表时间: 2005-02-24
影响因子: 158.5
作者:
Kobayashi, S;Boggon, TJ;Halmos, B
通讯作者: Halmos, B
DOI: 10.1038/onc.2010.556
发表时间: 2011-04-14
期刊: ONCOGENE
影响因子: 8
作者:
Hollander, M. C.;Maier, C. R.;Hobbs, E. A.;Ashmore, A. R.;Linnoila, R. I.;Dennis, P. A.
通讯作者: Dennis, P. A.
DOI: 10.1016/j.lungcan.2013.05.012
发表时间: 2013-09-01
期刊: LUNG CANCER
影响因子: 5.3
作者:
Li, Yuan-yuan;Lam, Sze-kwan;Ho, James Chung-man
通讯作者: Ho, James Chung-man
DOI: 10.1016/j.bmc.2005.12.035
发表时间: 2006-05-01
影响因子: 3.5
作者:
Fan, CD;Wang, WW;Miao, JY
通讯作者: Miao, JY